A double-blind, placebo-controlled, randomized phase III trial of chemotherapy plus epigenetic therapy with hydralazine valproate for advanced cervical cancer. Preliminary results. - Wikidata - wikimedia - TriplyDB

A double-blind, placebo-controlled, randomized phase III trial of chemotherapy plus epigenetic therapy with hydralazine valproate for advanced cervical cancer. Preliminary results.

A double-blind, placebo-controlled, randomized phase III trial of chemotherapy plus epigenetic therapy with hydralazine valproate for advanced cervical cancer. Preliminary results.

http://www.wikidata.org/entity/Q34142430

about

Epigenetic therapy in gastrointestinal cancer: the right combination Epigenetic treatment of solid tumours: a review of clinical trials Epigenetic Therapy for Solid Tumors: Highlighting the Impact of Tumor Hypoxia Aberrant DNA methylation in cervical carcinogenesis Developing epigenetic diagnostics and therapeutics for brain disorders The role of DNA methylation in aging, rejuvenation, and age-related disease Epigenetic modulators as therapeutic targets in prostate cancer Resistance after chronic application of the HDAC-inhibitor valproic acid is associated with elevated Akt activation in renal cell carcinoma in vivo Decitabine rescues cisplatin resistance in head and neck squamous cell carcinoma Valproate inhibits MAP kinase signalling and cell cycle progression in S. cerevisiae Systematic Review and Network Meta-Analysis of Bevacizumab Plus First-Line Topotecan-Paclitaxel or Cisplatin-Paclitaxel Versus Non-Bevacizumab-Containing Therapies in Persistent, Recurrent, or Metastatic Cervical Cancer.Seizure prognosis in brain tumors: new insights and evidence-based management Beyond angiogenesis blockade: targeted therapy for advanced cervical cancer.New molecular targets against cervical cancer.Promoter hypermethylation of KLF4 inactivates its tumor suppressor function in cervical carcinogenesis.Induction of Tet3-dependent Epigenetic Remodeling by Low-dose Hydralazine Attenuates Progression of Chronic Kidney Disease Histone Deacetylase Inhibitors (HDACi) Cause the Selective Depletion of Bromodomain Containing Proteins (BCPs).Valproic acid promotes radiosensitization in meningioma stem-like cells.Natural compound-derived epigenetic regulators targeting epigenetic readers, writers and erasers.Synergistic combination of valproic acid and oncolytic parvovirus H-1PV as a potential therapy against cervical and pancreatic carcinomas Emerging biological treatments for uterine cervical carcinoma.Molecular epigenetics in the management of ovarian cancer: are we investigating a rational clinical promise?Emerging drugs for cervical cancer.A pharmacokinetic evaluation of topotecan as a cervical cancer therapy.Effects of treatment with histone deacetylase inhibitors in solid tumors: a review based on 30 clinical trials.Management of advanced or recurrent cervical cancer: chemotherapy and beyond.Canonical and new generation anticancer drugs also target energy metabolism.Could valproic acid be an effective anticancer agent? The evidence so far.Targeting the histone orthography of cancer: drugs for writers, erasers and readers.Hydralazine-valproate: a repositioned drug combination for the epigenetic therapy of cancer.Emerging drugs for the treatment of cervical cancer.Impact of Histone Deacetylase Inhibitors on microRNA Expression and Cancer Therapy: A Review.Developmental DNA methyltransferase inhibitors in the treatment of gynecologic cancers.DNA methylation profiles in cancer diagnosis and therapeutics.Effects of In Utero Exposure to Ethinyl Estradiol on Tamoxifen Resistance and Breast Cancer Recurrence in a Preclinical Model.Rewiring the solid tumor epigenome for cancer therapy.Anti-neoplastic properties of hydralazine in prostate cancer.Investigational drugs for the treatment of cervical cancer.The antihypertensive drug hydralazine activates the intrinsic pathway of apoptosis and causes DNA damage in leukemic T cells.Epigenetic targeting drugs potentiate chemotherapeutic effects in solid tumor therapy.

P2860

Q26745709-7BB0A4A2-9AE3-449D-BA5A-A28085AC812D Q26773803-FACCB4FE-349E-479D-A97D-6EE1618C8982 Q26783014-38C9B7BB-461C-43F8-95B1-961425E6A480 Q26830289-053904DC-D7F2-420A-BC7F-89D5CCE081F3 Q27022987-B87B32EC-92CF-47A1-9ABA-C63DDFE49007 Q27025194-50ECF222-CF58-49F3-AD3F-5532669C28B6 Q28071912-64B0DAAD-C57C-420A-8D01-1428D917347B Q28485252-083971E1-5119-49E0-A163-4FB773BBD7A0 Q28544907-D1E4BF3D-C26F-4416-968B-80780B936235 Q28821030-C90EDB6C-B1C3-4C6C-BB9F-F19308AFC187 Q30491531-51969152-2628-44B6-9BF2-650FA2082AF3 Q33829789-341AD448-481E-4DEC-8D45-F79410C88637 Q33917356-44316CB6-D077-4D49-A060-C149382C1259 Q34700859-E1667EA3-C5C6-4C41-9BE9-9E980EAA1A52 Q35097588-EACBFBB8-CEF3-4A37-9F7E-B25B0C61A1D9 Q35110633-5DE35E96-A9FC-486D-91F5-9A9D555A17B7 Q35583360-43D1E3BC-AE25-4296-9DD3-8A418E069FA4 Q35833208-B97F53C6-C42F-4CAF-83F2-FF7377D627AB Q37114055-95F374EE-3ED1-4662-B87C-1048A134B0AE Q37237124-1568D010-7886-4BCA-B176-46B51F8C7B8D Q37540968-FFEF625E-8250-48D5-8BC9-55F3CD438948 Q37702543-838C050D-A847-4A3D-BDA6-4BCBFFB2BC47 Q38005222-B3D34E9E-F051-48CA-BC92-CE0AC7347918 Q38074207-47BFA873-4B6A-427E-A9C5-FBCE27321FB4 Q38081988-AB67E86F-1E4C-4F5D-B220-A6378A276E99 Q38178742-5E3A271C-D642-418E-BA54-826E9F3EB64A Q38208982-2AECD780-C496-4DC5-AFA1-96180B43FE60 Q38228823-46EFB1B6-E150-4827-9657-D850B460497D Q38231327-4F5F7BF1-421A-4594-A4EC-931C609C750B Q38242979-8338C301-B768-4EBC-883A-993C4596D10E Q38314157-CC957C8B-0830-45E5-8C3E-52CC373C2A98 Q38572855-3F1A9A30-124D-4B53-8DCE-56039662415D Q38630962-752B10DB-311B-43B6-807E-90EBF49CDCDE Q38650593-A7B231C8-9D0C-41D0-BC71-44B4671AD602 Q38747536-2C4ED2CE-3E53-47D9-ABB7-C2D8B83A2241 Q38895216-00DD484F-361F-4DB2-828D-872C8C575D48 Q38998403-E0B0965C-25C0-485A-B936-0187DA56EC5D Q39168925-88B3C9F1-23D0-4F8E-94EE-C9F7775B4F9A Q40996500-961BA03F-7D4C-4223-B20E-E2A5DBC693AB Q41064275-DF79262F-A6AD-4DBB-9534-290FE1520EF5

P2860

A double-blind, placebo-controlled, randomized phase III trial of chemotherapy plus epigenetic therapy with hydralazine valproate for advanced cervical cancer. Preliminary results.

http://www.wikidata.org/entity/Q34142430

description

2010 nî lūn-bûn

@nan

2010 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած

@hyw

2010 թվականի հոտեմբերին հրատարակված գիտական հոդված

@hy

2010年の論文

@ja

2010年論文

@yue

2010年論文

@zh-hant

2010年論文

@zh-hk

2010年論文

@zh-mo

2010年論文

@zh-tw

2010年论文

@wuu

name

A double-blind, placebo-contro ...... l cancer. Preliminary results.

@ast

A double-blind, placebo-contro ...... l cancer. Preliminary results.

@en

A double-blind, placebo-contro ...... l cancer. Preliminary results.

@nl

type

label

A double-blind, placebo-contro ...... l cancer. Preliminary results.

@ast

A double-blind, placebo-contro ...... l cancer. Preliminary results.

@en

A double-blind, placebo-contro ...... l cancer. Preliminary results.

@nl

prefLabel

A double-blind, placebo-contro ...... l cancer. Preliminary results.

@ast

A double-blind, placebo-contro ...... l cancer. Preliminary results.

@en

A double-blind, placebo-contro ...... l cancer. Preliminary results.

@nl

P1433

Q34142430-7FFCE6F6-F509-47A0-B45D-35FCC4213B95

P1476

Q34142430-98D0641A-BA9F-4CB1-8FBF-94DEC724A42C

P2093

Q34142430-27FC2C49-488B-44CF-B66E-2143A6B0C552

Q34142430-407C7EE8-D62E-4568-83B1-CCF5CF910FEE

Q34142430-5853E393-489F-41E9-A88B-B8C6C361CA85

Q34142430-8F6559A0-402A-481C-89C0-D99017C50C95

Q34142430-9BC03F5B-74F3-4BC3-8084-3B78BE9D6568

Q34142430-9DE3F6D0-9244-48CD-9EDD-D61A366B58C3

Q34142430-A1A75D97-D74C-4D1F-824D-9FA601EAF1C2

Q34142430-A964CD7F-2AAE-4C1E-986A-BFDD2CBF3C9F

Q34142430-BF1685D4-37E2-4327-8FB2-8FECEABB4356

Q34142430-DF22FBB4-1386-413B-BD70-39B8127A7644

P2860

Q34142430-01F11072-A899-4469-93AA-6C9CC7C46D08

Q34142430-09C1C2B7-5A87-47CF-A05D-D52714F41A94

Q34142430-20A5BFDC-56DC-4F5D-BC11-AD58A4D202F8

Q34142430-2D0FFBA9-3DB7-4172-8CA7-3C29CD9B7F24

Q34142430-2D5D681A-06F7-41F0-8911-40B0C43F68CA

Q34142430-38FDDE56-D0D1-4696-AC4E-1A33AD7B3B29

Q34142430-39217F79-76EF-4B35-A883-C35EDDB9AF84

Q34142430-395A264B-C443-44BB-9E5F-63EC3B8A45C7

Q34142430-39C74426-7D1F-4385-A812-54FA1858B721

Q34142430-3A36D0A7-4E9C-4484-8ED2-C3EE1E9A4D75

P2888

Q34142430-F42752CC-4F77-4870-B2D3-4D73B043D8BA

P304

Q34142430-5F0E0E73-0598-491E-883D-39FD3D7C05CF

P31

Q34142430-25F9DE8D-DD71-4B99-98A9-7ACA8E347D45

P356

Q34142430-522D250B-09A8-439B-B060-00C1CAE737DB

P478

Q34142430-9857009D-2427-46EB-AAE2-132423BA9FD9

P577

Q34142430-8EA6433E-1BDE-49B9-8013-636E8E2348DE

P6179

Q34142430-1906DFA1-44B2-4FC2-AB93-4525E0B9C40C

P698

Q34142430-DC1DCE65-CFF3-4140-B426-AB362D0CCB9D

P921

Q34142430-21A2BF81-F388-4DA1-A1C6-0C81B3F9D5DA

Q34142430-ACA0A0B9-9C63-44F2-AB3C-6C66B0E59D13

Q34142430-DBEDF83D-39D6-4C72-B350-A074B8AB81A4

P356

S12032-010-9700-3

P1433

Medical Oncology

P1476

A double-blind, placebo-contro ...... l cancer. Preliminary results.

@en

P2093

Alfonso Dueñas-González

http://www.w3.org/2001/XMLSchema#string

Aurora González-Fierro

http://www.w3.org/2001/XMLSchema#string

Catalina Trejo-Becerril

http://www.w3.org/2001/XMLSchema#string

Daymi Arias-Bofill

http://www.w3.org/2001/XMLSchema#string

Enrique Perez-Cardenas

http://www.w3.org/2001/XMLSchema#string

Erick de la Cruz-Hernandez

http://www.w3.org/2001/XMLSchema#string

Irlanda Pacheco

http://www.w3.org/2001/XMLSchema#string

Jaime Coronel

http://www.w3.org/2001/XMLSchema#string

Lucely Cetina

http://www.w3.org/2001/XMLSchema#string

Lucia Taja-Chayeb

http://www.w3.org/2001/XMLSchema#string

P2860

Up-regulation of HLA class-I antigen expression and antigen-specific CTL response in cervical cancer cells by the demethylating agent hydralazine and the histone deacetylase inhibitor valproic acid

A phase I study of hydralazine to demethylate and reactivate the expression of tumor suppressor genes

Histone acetylation and histone deacetylase activity of magnesium valproate in tumor and peripheral blood of patients with cervical cancer. A phase I study

Epigenetics of cervical cancer. An overview and therapeutic perspectives

Antineoplastic effects of the DNA methylation inhibitor hydralazine and the histone deacetylase inhibitor valproic acid in cancer cell lines.

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

Synergy of demethylation and histone deacetylase inhibition in the re-expression of genes silenced in cancer

Histone deacetylase is a direct target of valproic acid, a potent anticonvulsant, mood stabilizer, and teratogen

Induction of tumors in mice by genomic hypomethylation

Phase III trial of four cisplatin-containing doublet combinations in stage IVB, recurrent, or persistent cervical carcinoma: a Gynecologic Oncology Group study.

P2888

s12032-010-9700-3

P304

S540-6

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S12032-010-9700-3

http://www.w3.org/2001/XMLSchema#string

P478

28 Suppl 1

http://www.w3.org/2001/XMLSchema#string

P577

2010-10-08T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P6179

1015849576

http://www.w3.org/2001/XMLSchema#string

P698

20931299

http://www.w3.org/2001/XMLSchema#string

P921

phase III clinical trial